Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH) ("Nyxoah" או "החברה"), חברת טכנולוגיות רפואיות שמתמקדת בפיתוח ומסחור של פתרונות ושירותים חדשניים לדום נשימה בשינה (OSA) באמצעות נוירומודולציה, הודיעה היום על השקה מסחרית של מערכת Genio שלה במזרח התיכון, המבוססת על שתל Genio המוצלח הראשון שבוצע בבית החולים הגרמני הסעודי, דובאי – איחוד האמירויות הערביות, בתמיכת Odin Healthcare – בשיתוף פעולה עם Nyxoah באזור.
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East
First patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in the Middle East, marked by the first successful Genio implant performed at Saudi German Hospital, Dubai – United Arab Emirates, supported by Odin Healthcare – partnering with Nyxoah in the region.
The first patient was successfully implanted by Dr. Ahmed Yassin Bahgat, Consultant Otolaryngologist at Saudi German Hospital. Reflecting on this milestone, Dr. Bahgat stated: "We are honored to be the first hospital in the UAE, as well as the Middle East and Africa, to offer Genio to our OSA patients. Genio is an innovative, clinically proven, and smart therapy designed to effectively treat individuals with Obstructive Sleep Apnea who are unable to tolerate CPAP."
Olivier Taelman, CEO of Nyxoah, added: “The commercial launch of Genio in the UAE marks an historic milestone as the first-ever neurostimulation therapy for Obstructive Sleep Apnea in the region. We are proud to bring this groundbreaking, patient-centric solution to the Middle East, offering new hope to patients who cannot tolerate CPAP. With strong clinical evidence and growing global adoption, we remain committed to expanding access to Genio and transforming the treatment of OSA worldwide.”
About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
